Get the Stockscreener App
3.68
1.87%
-0.07
After Hours:
3.68
Zentalis Pharmaceuticals Inc stock is traded at $3.68, with a volume of 664.87K.
It is down -1.87% in the last 24 hours and up +6.05% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
See More
Previous Close:
$3.75
Open:
$3.71
24h Volume:
664.87K
Relative Volume:
0.38
Market Cap:
$261.68M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.7667
EPS:
-4.8
Net Cash Flow:
$-208.41M
1W Performance:
-9.36%
1M Performance:
+6.05%
6M Performance:
-76.65%
1Y Performance:
-81.66%
1-Day Range:
$3.60
$3.78
1-Week Range:
$3.60
$4.14
52-Week Range:
$2.83
$21.34
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Results from Zentalis Pharmaceuticals Inc (ZNTL) show potential - US Post News
Zentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News Summary - Benzinga
Decheng Capital LLC Has $12.56 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Holdings of Zentalis Pharmaceuticals Inc (ZNTL) are aligned with the stars - SETE News
Analyzing Ratios: Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Story Unveiled - The Dwinnex
Intech Investment Management LLC Raises Position in Zscaler, Inc. (NASDAQ:ZS) - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock - Benzinga
Should investors be concerned about Zura Bio Ltd (ZURA)? - US Post News
Holdings of Zevra Therapeutics Inc (ZVRA) are aligned with the stars - SETE News
Financial Metrics Unveiled: Zevra Therapeutics Inc (ZVRA)’s Key Ratios in the Spotlight - The Dwinnex
Zevra Therapeutics price target raised to $21 from $19 at Roth MKM - TipRanks
Zapata Computing Holdings Inc. (ZPTA) requires closer examination - US Post News
Zscaler, Inc. (NASDAQ:ZS) Shares Sold by ProShare Advisors LLC - MarketBeat
ZIVO Bioscience (NASDAQ:ZIVOW) Shares Down 60% - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by XTX Topco Ltd - MarketBeat
Understanding ZVRA’s financial ratios: A beginner’s guide - US Post News
A year in review: Zentalis Pharmaceuticals Inc (ZNTL)’s performance in the last year - US Post News
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Federated Hermes Inc. - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Sells 285 Shares of Zscaler, Inc. (NASDAQ:ZS) - Defense World
Massachusetts Financial Services Co. MA Invests $25.29 Million in Zscaler, Inc. (NASDAQ:ZS) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Federated Hermes Inc. - Defense World
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com
Zevra Therapeutics’ MIPLYFFA Wins FDA Approval for NPC - TipRanks
Zevra Therapeutics rises on US FDA approval for rare genetic disease treatment - XM
Zevra Therapeutics price target raised to $20 from $18 at H.C. Wainwright - TipRanks
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy - Benzinga
A stock that deserves closer examination: Zura Bio Ltd (ZURA) - US Post News
US FDA approves Zevra's genetic disorder treatment - XM
FY2024 EPS Estimates for Zevra Therapeutics, Inc. Reduced by Analyst (NASDAQ:ZVRA) - MarketBeat
Bank of New York Mellon Corp Boosts Position in Zumiez Inc. (NASDAQ:ZUMZ) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Bank of New York Mellon Corp - Defense World
Zenas BioPharma’s $225 Million IPO - Global Legal Chronicle
Zura Bio Ltd [ZURA] Director makes an insider sale of 3,800,000 shares worth 10,260,000. - Knox Daily
Canine dermatology drug gets FDA approval - VeterinaryPracticeNews.com
Zymeworks (NYSE:ZYME) Reaches New 1-Year High at $13.14 - MarketBeat
Clear Street LLC Grows Position in Zalatoris II Acquisition Corp. (NASDAQ:ZLS) - Defense World
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase ... - The Bakersfield Californian
Zenas BioPharma Announces Closing of Full Exercise of - GlobeNewswire
Zevra Therapeutics Inc (ZVRA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
The Zai Lab Limited ADR (ZLAB) had a good session last reading, didn’t it? - US Post News
Primecap Management Co. CA Increases Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zura Bio Ltd (ZURA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
J.W. Cole Advisors Inc. Buys Shares of 1,179 Zscaler, Inc. (NASDAQ:ZS) - Defense World
ZWS stock touches 52-week high at $34.62 amid market rally - Investing.com India
Zymeworks maintains price target post ESMO 2024 trial results By Investing.com - Investing.com Canada
Zscaler, Inc. (NASDAQ:ZS) CFO Sells $1,448,172.40 in Stock - Defense World
Zscaler CFO sells over $2.7 million in company stock - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com Canada
Wedbush lifts Zentalis Pharmaceuticals Inc [ZNTL] price estimate. Who else is bullish? - The DBT News
Trading Day Review: Zevra Therapeutics Inc (ZVRA) Loses Momentum, Closing at 7.53 - The Dwinnex
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):